VIDEO: Specialty drugs are critical focus for payers

June 3, 2013

News

Article

Leigh Ann Bruhn, director of Avalere Health, addresses results from "DIMENSIONS of Specialty Pharmaceuticals: Evolving Trends in Market Access," a new study conducted by Avalere Health and commissioned by Janssen Biotech, Inc. and Johnson & Johnson Health Care Systems.

Read the full story here.

Related Content

FDA Expands Kerendia’s Use to Treat Common Form of Heart Failure

Briana Contreras

July 14th 2025

Article

Kerendia was originally approved in July 2021 to reduce cardiovascular and kidney complications in patients with chronic kidney disease (CKD) associated with type 2 diabetes. This new approval extends its use to a broader patient population.

FDA Approves Ekterly, First Oral Treatment for Hereditary Angioedema

Logan Lutton

July 7th 2025

Article

Orsini will be the specialty pharmacy partner for Ekterly.

Lynozyfic Shows 70% Response Rate in Heavily Pre-Treated Multiple Myeloma Patients, FDA Grants Accelerated Approval

Briana Contreras

July 2nd 2025

Article

According to Regeneron, the drug is a bispecific antibody that binds to B-cell maturation antigen (BCMA) on cancerous plasma cells and CD3 on T cells, directing the immune system to attack and destroy multiple myeloma cells.

Optum Rx Eliminates Reauthorization on an Additional 60 Drugs

Denise Myshko

June 30th 2025

Article

Optum Rx officials said they now have eliminated reauthorization requirements for more than 140 chronic disease medications.

Prime Study Finds Low Long-Term Adherence to GLP-1 Obesity Drugs

Denise Myshko

June 26th 2025

Article

A separate Prime analysis, however, of year-over-year claims data for Wegovy and Zepbound only found an improvement in adherence in 2024, suggesting there is an evolving understanding of obesity treatment.